Last reviewed · How we verify

Zolpidem + PAP therapy

VA Office of Research and Development · FDA-approved active Small molecule

Zolpidem enhances GABAergic inhibition in the central nervous system to promote sleep, while PAP (positive airway pressure) therapy mechanically maintains airway patency during sleep.

Zolpidem enhances GABAergic inhibition in the central nervous system to promote sleep, while PAP (positive airway pressure) therapy mechanically maintains airway patency during sleep. Used for Insomnia in patients with obstructive sleep apnea on PAP therapy, Sleep maintenance disorder in sleep apnea patients.

At a glance

Generic nameZolpidem + PAP therapy
SponsorVA Office of Research and Development
Drug classSedative-hypnotic (non-benzodiazepine) + mechanical airway support device
TargetGABA-A receptor (zolpidem component); mechanical airway (PAP component)
ModalitySmall molecule
Therapeutic areaSleep Medicine / Neurology
PhaseFDA-approved

Mechanism of action

Zolpidem is a sedative-hypnotic that binds to GABA-A receptors, increasing inhibitory neurotransmission and facilitating sleep onset and maintenance. PAP therapy (CPAP, BiPAP, or APAP) delivers pressurized air to prevent airway collapse in obstructive sleep apnea. This combination addresses both the sleep initiation/maintenance deficit and the underlying airway obstruction characteristic of sleep apnea.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: